

Pr. Jean-Yves BLAY, M.D, Ph.D

jean-yves.blay@lyon.unicancer.fr

Conseil National de l'Ordre des Médecin Français (CNOM) : 69/10280

N° RPPS : 8 10003059382 250323461

Website : <https://orcid.org/0000-0001-7190-120X>

Born December 2, 1962 in Montélimar, Drôme, France French citizen

Professional address:

- Dpt Medecine & INSERM 1052 & Université Claude Bernard Lyon
- Centre Léon Bérard - 28 rue Laënnec - 69373 LYON Cedex 08
- UNICANCER, 101, rue de Tolbiac , Paris France



Lyon Feb 2022

Signature :

Hospital and University positions

- President of UNICANCER the Federation of Comprehensive Cancer Centers in France
- General Director of the Centre Leon Berard, Lyon France www.centreleonberard.fr (2014-ongoing)
- Professor of Medical Oncology, Classe exceptionnelle (2012), UCBL1
- Director of the H2020 ERN on Rare Solid Tumors (EURACAN H2020 739521) (2016-ongoing)
- Scientific director of AURAGEN (AURA platform, FMG2025) (2017-ongoing)
- Head of the Medicine Department of the Lyon Cancer Center (Centre Léon Bérard, CLB) (2009-14)
- Head of the French NCI Integrated site of Innovative Research on Cancer (LYRIC, grant INCA_4664) then since 2017 of LYRICAN, (INCa_INSERM_DGOS_12563).(2011-ongoing)
- Director of the Network of Reference Centers for sarcomas in France NETSARC+ (26 centers, Netsarc.org) (2010+)
- Chairman of the French Sarcoma Group (www.gsf-geto.org) (2006-ongoing)
- Corresponding member of the French National Academy of Medicine (2014+)

Training

- 1979: First year medical school (1979); 1986: Graduated in the Academic Hospitals : concours internat Lyon (3rd) and Paris ; 1988 : Master 2 Bases Fondamentales de l'oncogenèse, University Paris VII ; 1989: Master 1 in Statistics, (University Paris XI); 1990 : Doctor in Medicine (Lyon 1990)- Thesis Medicine, October 1990
- 1990 : D.E.S. (Board Certified) for Medical Oncology, (Lyon, 1989); 1991 : Basic Medical and Clinical Science Components of the Foreign Medical Graduate Examination in the Medical Sciences (FMGEMS), Educational Commission for Foreign Medical Graduates (ECFMG)
- 1994: Ph. D. Thesis, University Claude Bernard, Lyon I, France.
- 1996: Habilitation à diriger les recherches (Research training, highest level of French Universities)

Principal international positions

- President of the European Organisation for Research and Treatment of Cancer –EORTC (2009-2012)
- European Society of Medical Oncology (ESMO) Faculty Coordinator for Sarcoma for 2012-2016.
- Director of The European Reference Network EURACAN (106 centers, 26 countries, euracan.org) (2017-ongoing)
- Scientific President of ESMO 2019 Congress, (Barcelona, 29949 participants)

Research activities (biology)

- 1990-1994: Ph.D: Role of IL-6 in the biology of renal cell carcinoma
- 1994-2010: Head of the Cytokine and Cancer Unit, UNSERM U590 Centre Leon Berard
- 2011-18: Co-chair of the INSERM U1052 Centre Léon Bérard (crcl.fr), Team 11.
- 2019+: Co-chair of the INSERM U1052 Centre Léon Bérard (crcl.fr), Team 27.

Research management activities (clinical and basic)

- Chairman of the French Sarcoma Group (www.gsf-geto.org) (2005+)
- Secretary of the World Sarcoma Network (Network of all national sarcoma groups worldwide) (2009+)
- Director of NETSARC : Network of Reference Centers for sarcomas in France (26 centers, Netsarc.org) (2010+)
- Head of the French NCI Integrated site of Innovative Research on Cancer (LYRIC, grant INCA_4664) then since 2017 of LYRICAN, (INCa_INSERM_DGOS_12563).
- Principal investigator (N=23, 2021: N=7) and co-investigator (N=174) in national & international clinical trials since 1993. Good Clinical Practice certificate May 2019.

Honors and Prizes

- Laureate of the Prize Maurice Carraz of the Institut Pasteur Lyon (1990).
- Laureate of the Prize Savoie of the Conseil Scientifique National de la Ligue contre le Cancer (1991).
- Laureate and Grantee of the Estée Lauder Prize for Breast Cancer Research (2005-2008);
- Laureate of the Tartois Prize (2010)
- Laureate of the Hamilton Fairley Prize, European Society of Medical Oncology (2012)
- Laureate of the Henry and Maryjane Mitjaville Prize of the French Natl Academy of Medicine (2013)
- Nina Axelrad Lecture and Prize, Connective Tissue Oncology Society, Rome (Nov 2018)
- Prix Duquesne, Comité de Paris de la Ligue contre le Cancer, (Sept 2020)
- San Salvatore Prize, San Salvatore Foundation, Switzerland (Nov 2020)

Research evaluator and referee

- Member of Fondation pour la Recherche Medicale Scientific Advisory Board (2012-2016)
- Member of Association pour la Recherche sur le Cancer Scientific Advisory Board (2012-2017)
- Referee for various international funding agencies (Spanish Ministry of Research, Italian Ministry of Research, MRC UK, Cancer Research UK, Deutsche KrebsHilfe, Swiss Cancer League; Belgian League Australian Sarcoma Group, Chinese CRTER, Liddy Shriver Sarcoma initiative ...)
- Referee for International Universities (Harvard Boston, Cornell, FoxChase Philadelphia, Helsinki, Leeds, York, Koweit City, Oxford)
- Referee for various international journals (New Engl J Med, Lancet, Cancer Cell, Nature Medecine, Lancet Oncol, J Clin Oncol, Cancer Research, Ann Oncology, Eur J Cancer, Oncogene...)

European grants

- Director of the **CONTICANET** Network of excellence (6th FP, European Commission) (FP6-018806) (Grant 9.6 M€) (conticabase.org, conticagist.org)
- Director of the **EUROSARC** (7th FP, European Commission) (FP7-278472) (eurosarc.eu) (2010-15)
- **EURACAN** European reference Network (2017-2022)

A selection of important grants (>1 M€)


- *Estée Lauder Breast Cancer Research Foundation (2005-2009) (250000 dollars yearly);*
- *FP6 Conticanet (LSHC-CT-2005-018806, 9.6 M€, 2006-2011)*
- *FP7 EUROSARC (FP7-278472) (5.9 M€, 2012-2018)*
- *Institut National du Cancer (INCA) SIRIC LYRIC, (11,5 M€), (2011-2017) ;*
- *Institut National du Cancer (INCA) NETSARC (4 M€) (2011-2015)*
- *Institut National du Cancer (INCA) LYRICAN, (INCa_INSERTM_DGOS_12563, 5 M€), (2018-2022)*
- *AURAGEN plan FMG2025, INSERM MSS, MESR (2017-2025)*
- *EURACAN (Grant number 739521) European Reference Network for rare cancers (2017-2022)*
- *DiaGnose: Artificial intelligence in cancer diagnostics, Fondation MSDAvenir (2018-2021)*
- *Health Data Hub program DeepSARC (Ministry of Research, France (2019-2021)*
- *RHU4 program DEPGYN (Ministry of Research, ANR, (2020-2023)*

Patents

Patents: *IL6t* (US patent 10/496.793); *Biomarker IGF1R* (WO2009/079587 A2; US7,811,562 B2; EP1828249 B1 application number 11305914.1-2301); TcR diversity (EP/09.12.09/EPA09290922, appl. # 10803594.0-1222 PCT FR2010000829); *Sumscan Genomic classifier* (EP/19.12.14/EPA 14307115; appl#15816152.1-1403); *VNN1 in sarcoma* (EP/25.09.17/EPA17306259, appl. #18770060.4-111)

Publications & Bibliometry

Clarivate Web of Science Highly Cited Researcher 2019 & 2020 & 2021

- **Pubmed** : N=880 publications (Blay JY or Blay J excluding homonyms) since 1987, including 118 in first author, 225 in last author. 33 highly cited papers- 12/03/2022 ( Highly Cited Paper)
- **Web of science** : N=1630 publications, **H index=116, 12/03/2022**
- **ResearchGate**: H Index =127; RGscore: 56,8
- **Sigaps score**: March 2022 13197 (with abstracts) 11768 (w/o abstracts).
- **Google Scholar Citations** 76417, **H index: 136** (since 2017 citations 36307, H index 96)
Google Scholar Highly cited researcher Google (<http://www.webometrics.info/en/node/58>)